LATEST NEWS   New legislation on gig workers in the pipeline - DPM Ahmad Zahid | 

CopilotIQ, Biofourmis Merger To Create Maiden AI-driven In-home Care Platform

KUALA LUMPUR, Oct 22 (Bernama) -- CopilotIQ, a health tech company, has announced a strategic merger with Biofourmis, a global technology-enabled care delivery company, to create the industry's first artificial intelligence (AI)-driven platform that delivers in-home care across the full spectrum from pre-surgical optimisation to acute, post-acute, and chronic care.

The newly combined entity CopilotIQ and Biofourmis Chief Executive Officer, David Koretz said the company’s mission is to redefine the future of healthcare delivery by extending care to the comfort of patients’ homes and driving improved health outcomes, at the lowest possible cost to the system.

“This merger is a major step toward realising our vision of transforming healthcare from reactive treatment to proactive prevention and from generalised to deeply personalised, data-driven care,” he said in a statement.

For customers, the combination delivers a single vendor that can provide a best-in-class offering across the entire care continuum and creates a ‘single pane of glass’ solution by which enterprise customers will enjoy observability of patients across the care continuum via one technology integration, one security audit, simplified procurement, and a much better patient experience.

Biofourmis’ capabilities in supporting health systems, payors, and life sciences companies’ delivery of complex care for their patients in the home with Food and Drug Administration (FDA)-cleared algorithms and technology will be expanded further upstream and downstream when combined with CopilotIQ.

The combined company will unlock coordinated, convenient, and cost-effective care for patients managing chronic conditions.

In addition, CopilotIQ’s transformative software suite for driving patient engagement, improving clinician efficiency, and delivering clinical personalisation, will be integrated across Biofourmis’ acute and post-acute offerings.

As part of this combination, leading investors from both businesses, including General Atlantic, Openspace Ventures, and Bessemer Venture Partners, are investing in the combined business.

-- BERNAMA